12:00 AM
Jul 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Contrave: Phase III data

In the double-blind, U.S. Phase III COR-Diabetes (NB-304) trial in 424 evaluable Type II diabetics, Contrave (32 mg naltrexone SR/360 mg bupropion SR) met the co-primary endpoints of the proportion of patients achieving ?5% body weight loss compared with placebo at week 56 (44.5% vs. 18.9%, p<0.001) and percent change in body weight vs. placebo at week 56 (5% vs. 1.8%, p<0.001)....

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >